|
A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). |
|
|
Honoraria - Celgene; Roche |
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Consulting or Advisory Role - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Roche; Teva |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Genomic Health; Novartis; Roche |
Consulting or Advisory Role - Roche |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Roche |
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Myriad Genetics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Teva (Inst); Vifor Pharma (Inst) |
|
|
Research Funding - Amgen (Inst); Roche (Inst); Teva (Inst); Vifor Pharma (Inst) |